Ratings by Brookline Capital Markets (Sally Yanchus)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/22/2025 | Bioceres Crop Solutions | BIOX | Downgrade | Hold (Buy) |
2.94 (0.33) |
-88.78% | Details | |
| 9/11/2020 | DermTech Inc. | DMTK | New Coverage | Buy (N/A) |
10.65 (0.09) |
-99.15% | Details | |
| 8/17/2020 | 9 Meter Biopharma | NMTR | New Coverage | Buy (N/A) |
0.57 (0.07) |
-87.72% | Details | |
| 7/15/2020 | Antibe Therapeutics | ATBPF | New Coverage | Buy (N/A) |
0.28 (0.22) |
-21.43% | Details | |
| 6/18/2020 | Lexagene Holdings | LXXGF | New Coverage | Buy (N/A) |
0.57 (0.08) |
-85.96% | Details | |
| 6/3/2020 | Assertio Therapeutics | ASRT | New Coverage | Buy (N/A) |
1.00 (23.50) |
2250% | Details | |
| 5/14/2020 | Biocept | BIOC | New Coverage | Buy (N/A) |
0.44 (0.43) |
-2.27% | Details | |
| 4/28/2020 | Dare Bioscience | DARE | New Coverage | Buy (N/A) |
1.04 (1.62) |
55.77% | Details | |
| 4/14/2020 | Bellerophon Therapeutics | BLPH | New Coverage | Buy (N/A) |
11.42 (0.01) |
-99.91% | Details | |
| 2/5/2020 | Bioceres Crop Solutions | BIOX | New Coverage | Buy (N/A) |
4.95 (2.94) |
-40.61% | Details |
